Icu Medical, Inc. · NASDAQ:ICUI
Icu Medical — Q3 2024 Earnings Presentation
10 slides from Icu Medical's earnings presentation, Nov 12, 2024
Slide 1: ICU Medical, Inc Q3 2024 Conference Call Presentation
ICU Medical, Inc Q3 2024 Conference Call Presentation November 12, 2024
Slide 2: Disclosures
Disclosures > Any statement concerning Management’s expectation with respect to future results is a forward-looking statement based upon the best information currently available to Management and assumptions Management believes are reasonable, but Management does not intend the statement to be a rep
Slide 3: 2023–2024 Adjusted Revenue
2023–2024 Adjusted Revenue In $ millions, unaudited 3
Slide 4: Joint Venture to Bolster IV Solutions Manufacturing and Innovation in the North American Market
Together Announce Joint Venture to Bolster IV Solutions Manufacturing and Innovation in the North American Market Nov. 12, 2024
Slide 5: Otsuka Group Profile
Otsuka Group Profile Founded in 1921, Otsuka is a leading manufacturer of IV solutions outside North America and pharmaceutical products globally, aiming to create innovative products that meet a variety of clinical needs. Otsuka Holdings CY2023 Financial Overview Market Capitalization (Nov. 2024) ~
Slide 6: Otsuka Track Record of Innovation and Full PVC-Free Portfolio
Otsuka Track Record of Innovation and Full PVC-Free Portfolio Admixture Parenteral Nutrition: TPN Parenteral Nutrition: PPN Premix, Ready-to-Use > Convenient containers > Multi-chamber bags (MCBs), > Dual-chamber bags for peripheral > The world’s first premix IV that are easy to handle including the
Slide 7: Why Otsuka Transaction Highlights
ICU Medical was deeply attracted to Otsuka Why Otsuka for a set of core reasons: > Scale and redundancy > Commitment to innovation > Cultural mindset and willingness to invest long-term > Financial strength > Demonstrated partnership experience in the U.S. Key economic terms of the Joint Venture: Tr
Slide 8: JV Becomes Part of Manufacturing Network with Scale and Redundancy
JV Becomes Part of Manufacturing Network with Scale and Redundancy Creates one of the largest IV solutions manufacturing networks on the planet > Supporting supply resiliency with long-term goal of FDA approval for relevant manufacturing sites ~1.4B annual units of combined production 17 combined gl
Slide 9: Otsuka: A Strong, Like-Minded Partner with Valuable Experience
Otsuka: A Strong, Like-Minded Partner with Valuable Experience Financial Strength Cultural Mindset U.S. Partnership Experience > Significant financial strength allows “Creating new products Otsuka & Bristol-Myers Squibb for long-term investment for better health worldwide.” Co-develop and co-commerc
Slide 10: Transaction Structure Key Items
Transaction Structure Key Items > Joint Venture estimated to be operationally effective early Q2 2025 Joint Venture > ICU Medical will provide commercial services for Joint Venture to Setup ensure seamless operations for North American customers > ICU Medical will provide certain transition services